/AKBM.OL

AKBM.OL Stock - Aker BioMarine AS

Q: What is the analyst price target for AKBM.OL?

Analyst price target information is not currently available for AKBM.OL.

Q: What is AKBM.OL's market cap?

Market capitalization information is not currently available for AKBM.OL.

Consumer Defensive|Packaged Foods|OSL

$91.00+1.79%

+$1.60 (+1.79%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $100.10

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AKBM.OL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.36

52W High$94.30

52W Low$43.65

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$199.00M	$335.30M	$277.20M	$262.06M	$288.59M
Gross Profit	$69.10M	$112.90M	$114.80M	$88.06M	$109.58M
Gross Margin	34.7%	33.7%	41.4%	33.6%	38.0%
Operating Income	$-6,500,000	$5.30M	$22.10M	$5.84M	$18.47M
Net Income	$180.30M	$-9,000,000	$10.00M	$-8,008,000	$-5,463,000
Net Margin	90.6%	-2.7%	3.6%	-3.1%	-1.9%
EPS	$-0.16	$-1.32	$0.11	$-0.09	$-0.07

Company Overview

Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.

Visit Website

Earnings History & Surprises

AKBM.OL

Beat Rate

38%

Last 16 quarters

Avg Surprise

-421.7%

EPS vs Estimate

Beats / Misses

6/10

Last 12 quarters

Latest EPS

$-1.68

Q3 2025

EPS Surprise History

Q4 23

-66.7%

$0.01vs$0.03

Q1 24

+350.0%

$0.18vs$0.04

Q2 24

No data

Q3 24

-14.3%

$0.03vs$0.04

Q4 24

+125.0%

$0.09vs$0.04

Q1 25

-233.3%

$-0.08vs$0.06

Q2 25

-80.7%

$-0.38vs$-0.21

Q3 25

-6925.0%

$-1.68vs$0.02

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 28, 2026	—	—	—	—
Q1 2026	Feb 10, 2026	—	—	—	—
Q4 2025	Oct 31, 2025	$0.05	—	—	—
Q3 2025	Jul 11, 2025	$0.02	$-1.68	-6925.0%	✗ MISS
Q2 2025	Apr 30, 2025	$-0.21	$-0.38	-80.7%	✗ MISS
Q1 2025	Feb 12, 2025	$0.06	$-0.08	-233.3%	✗ MISS
Q4 2024	Nov 1, 2024	$0.04	$0.09	+125.0%	✓ BEAT
Q3 2024	Jul 12, 2024	$0.04	$0.03	-14.3%	✗ MISS
Q2 2024	Apr 26, 2024	—	$-1.48	—	—
Q1 2024	Feb 14, 2024	$0.04	$0.18	+350.0%	✓ BEAT
Q4 2023	Nov 1, 2023	$0.03	$0.01	-66.7%	✗ MISS
Q3 2023	Jul 14, 2023	$-0.01	$-0.03	-175.0%	✗ MISS
Q2 2023	Apr 28, 2023	$-0.10	$-0.20	-100.0%	✗ MISS
Q1 2023	Feb 15, 2023	$0.10	$0.03	-70.0%	✗ MISS
Q4 2022	Nov 1, 2022	$0.10	$0.05	-50.0%	✗ MISS
Q3 2022	Jul 14, 2022	$0.02	$0.09	+324.9%	✓ BEAT
Q2 2022	Apr 29, 2022	$-0.14	$-0.10	+28.6%	✓ BEAT
Q1 2022	Feb 17, 2022	$-0.15	$-0.09	+40.0%	✓ BEAT
Q4 2021	Oct 29, 2021	$-0.09	$0.18	+300.0%	✓ BEAT
Q3 2021	Jul 14, 2021	$-0.01	$-0.04	-200.1%	✗ MISS

Frequently Asked Questions about AKBM.OL

What is AKBM.OL's current stock price?

Aker BioMarine AS (AKBM.OL) is currently trading at $91.00 per share. The stock has moved +1.79% today.

What is the analyst price target for AKBM.OL?

No analyst price targets are currently available for this stock.

What sector is Aker BioMarine AS in?

Aker BioMarine AS operates in the Consumer Defensive sector, specifically within the Packaged Foods industry. The company is traded on the OSL exchange.

What is AKBM.OL's market cap?

Aker BioMarine AS has a market capitalization of $7.98 billion, making it a mid-cap company.

Does AKBM.OL pay dividends?

No, Aker BioMarine AS does not currently pay a dividend to shareholders.